Optinose Stock Price, News & Analysis

Optinose (NASDAQ:OPTN) will report its second quarter 2022 financial results on August 11, 2022, prior to market open. The conference call for discussing these results and corporate updates is scheduled for 8:00 a.m. Eastern Time on the same day. Participants can join the call via webcast or by registering for a telephone connection. A replay of the event will be available on the company's website for 60 days. For more information about Optinose and its focus on ENT and allergy treatments, visit www.optinose.com.

Optinose (NASDAQ:OPTN) announced pivotal results from the ReOpen trials, showcasing its drug XHANCE as the first nasal medication to significantly reduce chronic sinusitis exacerbations. A pre-planned analysis revealed a notable 66% reduction in exacerbations with XHANCE (372 mcg) versus placebo over 24 weeks. Chronic sinusitis leads to approximately 10 million outpatient visits annually, heavily contributing to antibiotic prescriptions. XHANCE could transform treatment, reducing reliance on antibiotics and improving patient quality of life.

Optinose announced results from the ReOpen trials, evaluating XHANCE for chronic sinusitis treatment. The trials demonstrated significant symptom relief and improved quality of life in patients using XHANCE compared to placebo. Key findings include improved scores on congestion, facial pain, and quality of life metrics over 24 weeks, with significant p-values (<0.05). Notably, XHANCE showed a 6.31% reduction in sinus opacification in patients without nasal polyps versus a 1.55% reduction for placebo. The safety profile aligns with expectations, with increased rates of epistaxis and headaches noted.

Optinose announced significant results from the Phase 3 ReOpen2 trial for XHANCE, a nasal therapy for chronic sinusitis without nasal polyps. The trial, involving 222 patients, showed marked improvement in both symptoms and inflammation, fulfilling co-primary endpoints. This is the first evidence supporting effective treatment for a large population lacking FDA-approved medications. With potential for a new indication, Optinose aims to expedite analyses of both ReOpen trials and pursue expanded access to XHANCE, promising new hope for millions affected by chronic sinus disease.

Optinose (NASDAQ:OPTN) announced key leadership changes as Keith A. Goldan, CFO, departs for another opportunity, effective June 10, 2022. Michele Janis, VP of Finance, is appointed Acting CFO, while Anthony Krick becomes Vice President and Chief Accounting Officer. CEO Peter Miller praised Goldan’s contributions during the company's transition to a public entity. Janis and Krick are expected to maintain strong financial oversight and investor communication.

Optinose (NASDAQ:OPTN) reported a 35% increase in net revenue for XHANCE, reaching $14.8 million in Q1 2022 compared to Q1 2021. The company anticipates full-year net revenue of at least $90 million for XHANCE. Notably, XHANCE prescriptions grew by 11%, with new prescriptions up 9%. The ReOpen1 clinical trial achieved both co-primary endpoints, showing significant improvement in chronic sinusitis patients. However, the company posted a net loss of $25.3 million for Q1 2022 and expects operating expenses between $135-$140 million for the year.

Optinose (NASDAQ:OPTN) will report its first-quarter 2022 financial results and corporate updates on May 12, 2022, before market open. A conference call hosted by the leadership team is scheduled for the same day at 8:00 a.m. Eastern Time. Participants can join the call by dialing the provided numbers or accessing a simultaneous webcast on the company’s website. A replay of the call will be available until May 19, 2022. Optinose specializes in pharmaceuticals for ear, nose, and throat (ENT) and allergy care, focusing on patient needs.

Optinose (NASDAQ:OPTN) announced the appointment of R. John Fletcher as a Class III director to its Board of Directors. He brings over 30 years of strategy and finance experience in the healthcare and pharmaceutical sectors. Fletcher’s previous roles include founding Fletcher Spaght Inc. and serving as a Senior Manager at The Boston Consulting Group. His expertise will contribute to enhancing shareholder value. The company also signed a Cooperation Agreement with Kingdon Capital and Velan Capital regarding this appointment.

Optinose (NASDAQ:OPTN), a specialty pharmaceutical company, will present a company overview and business update at the Needham Virtual Healthcare Conference on April 12, 2022, at 11:45 a.m. ET. Interested parties can listen to the live webcast on Optinose's Investors page, with a replay available for 60 days post-event. The company focuses on patients treated by ENT and allergy specialists. For more information, visit www.optinose.com.